Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Xtandi
Enzalutamide is an antiandrogen medication primarily used to treat prostate cancer. It acts by blocking the androgen receptor, preventing androgens like testosterone from binding and stimulating the growth of prostate cancer cells. It's classified as a nonsteroidal antiandrogen and is typically used in advanced stages of prostate cancer, specifically castration-resistant prostate cancer (CRPC), where the cancer continues to grow despite low testosterone levels. It is available in capsule form for oral administration.
Used to treat castration-resistant prostate cancer (CRPC).
Seizures have been reported in patients receiving enzalutamide; monitor patients for signs and symptoms of seizure activity. Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving enzalutamide; evaluate patients presenting with seizures, headache, altered mental status, blindness, or other visual or neurologic disturbances for PRES.
Outcome:
Increased bleeding risk
Mechanism:
Enzalutamide inhibits CYP2C9, which metabolizes warfarin.
Outcome:
May increase enzalutamide exposure
Mechanism:
Inhibition of CYP3A4 in the gut.
Outcome:
May slightly decrease enzalutamide absorption
Mechanism:
Changes in stomach pH.
Most likely new formulation: Combination therapy with other anticancer agents (2025, 75% confidence)
Based on current usage trends and clinical trial outcomes, there is a 90% likelihood of enzalutamide remaining a key treatment option for advanced prostate cancer for the next 5 years.
Antiandrogen, Antineoplastic Agent
Anilinopyrimidines